Abstract: Melanoma is one of the most lethal cutaneous malignancies, characterized by chemoresistance and a striking propensity to metastasize. The transcription factor ATF2 elicits oncogenic activities in melanoma, and its inhibition attenuates melanoma development. Here, we show that expression of a transcriptionally inactive form of Atf2 (Atf2(Δ8,9)) promotes development of melanoma in mouse models. Atf2(Δ8,9)-driven tumors show enhanced pigmentation, immune infiltration, and metastatic propensity. Similar to mouse Atf2(Δ8,9), we have identified a transcriptionally inactive human ATF2 splice variant 5 (ATF2(SV5)) that enhances the growth and migration capacity of cultured melanoma cells and immortalized melanocytes. ATF2(SV5) expression is elevated in human melanoma specimens and is associated with poor prognosis. These findings point to an oncogenic function for ATF2 in melanoma development that appears to be independent of its transcriptional activity. 
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Claps et al. demonstrate that a transcriptionally inactive isoform of ATF2 lacking exons 8 and 9 is sufficient to promote melanoma in mouse models. They also identify a transcriptionally inactive human splice variant of ATF2, which resembles the mouse isoform, that is expressed in melanoma specimens and is associated with poor prognosis.
SUMMARY
Melanoma is one of the most lethal cutaneous malignancies, characterized by chemoresistance and a striking propensity to metastasize. The transcription factor ATF2 elicits oncogenic activities in melanoma, and its inhibition attenuates melanoma development. Here, we show that expression of a transcriptionally inactive form of Atf2 (Atf2 D8,9 ) promotes development of melanoma in mouse models. Atf2 D8,9 -driven tumors show enhanced pigmentation, immune infiltration, and metastatic propensity. Similar to mouse Atf2 D8,9
, we have identified a transcriptionally inactive human ATF2 splice variant 5 (ATF2 SV5 ) that enhances the growth and migration capacity of cultured melanoma cells and immortalized melanocytes. ATF2 SV5 expression is elevated in human melanoma specimens and is associated with poor prognosis. These findings point to an oncogenic function for ATF2 in melanoma development that appears to be independent of its transcriptional activity.
INTRODUCTION
Melanoma is one of the most lethal cutaneous malignancies due to its metastatic propensity and resistance to therapy (Lo and Fisher, 2014) . Rewired signal transduction pathways, which underlie melanoma lethality, are driven by networks of protein kinases and related transcription factors. Activating Transcription Factor 2 (ATF2) is a member of the ATF/CREB bZIP family of transcription factors, which heterodimerizes with members of the JUN and FOS transcription factor families Lopez-Bergami et al., 2010) .
In melanoma, nuclear ATF2 expression is associated with poor prognosis and metastatic burden, whereas cytoplasmic localization correlates with sensitization of melanoma to genotoxic stress and better clinical outcome (Berger et al., 2003) . Consistent with this, inhibition of ATF2 reduces melanoma growth in BRAF and NRAS mutant melanoma cell lines in culture and in xenografts (Bhoumik et al., 2002 (Bhoumik et al., , 2004a (Bhoumik et al., , 2004b . Also in agreement, Nras Q61K ;Ink4a
mice selectively expressing the transcriptionally inactive form of Atf2 (Atf2 D8,9 ), which lacks the DNA-binding domain and part of the leucine zipper domain (Breitwieser et al., 2007) , show attenuated melanoma development (Shah et al., 2010) .
In contrast, mice without melanoma susceptibility genes, but harboring Atf2 D8,9 selectively expressed in keratinocytes, display increased papilloma development when subjected to a two-stage skin carcinogenesis protocol (Bhoumik et al., 2008) . Similarly, mouse embryonic fibroblasts expressing Atf2 D8,9 , but lacking its homolog ATF7, show increased proliferation and formation of tumors exhibiting a JNK-ATF2-dependent gene signature in orthotopic liver cancer models (Gozdecka et al., 2014) . Likewise, mutant p53 mice with deletions in the Atf2 DNA-binding domain (amino acids 327-395) develop mammary tumors (Maekawa et al., 2008) .
These observations suggest that ATF2 oncogenic or tumor suppressor function varies among tumor and tissue types depending on the landscape of genetic factors. Here, we assessed the role of ATF2 in a well-characterized genetic mouse model of Braf/Pten mutant melanoma (Dankort et al., 2009) . Surprisingly, we found that transcriptionally inactive Atf2 D8,9 has a tumor-promoting effect in Braf mutant melanocytes, which is enhanced in Braf/Pten mutant animals. ) (Shah et al., 2010) WT/D8, 9 ;Braf V600E/V600E ;Pten À/À (n = 18) mice ( Figure S1A , upper). 4-HT-treated Atf2 D8,9/D8,9 mice were more heavily pigmented than Atf2 WT/WT animals (Figure 2A) . Increased pigmentation was seen throughout the dermis and subcutis of Atf2 D8,9/D8,9 mice (n = 6) compared with Atf2 WT/WT controls (n = 6), with spreading into the epidermis ( Figure 2B ). Despite these changes, the median survival time of the Atf2 WT/WT , Atf2 D8,9/D8,9 , and Atf2 WT/D8,9 mice did not differ (18-19 days) , possibly due to the rapid melanoma development in this model ( Figure S1B ).
RESULTS

Atf2
To monitor tumor growth over a prolonged period, we administered 4-HT locally on the dorsal skin of 3-week-old Atf2 WT developed larger tumors ( Figure 2C ) that appeared earlier in control mice ( Figure 2D ). The median survival time of Braf V600E/V600E ; Pten À/À mice was decreased from 64 to 47 days by Atf2 D8,9/D8,9 expression ( Figure 2E ). The Atf2 D8,9/D8,9 mice had a larger number of highly pigmented cells, which were confirmed to be of melanocytic origin based on S100 immunostaining ( Figure 2F ). These data suggest that expression of Atf2 D8,9 in Braf V600E/V600E ; Pten À/À mice promotes melanoma development. S100 staining revealed an increased number of metastatic melanoma cells in the lymph nodes of ATF2 D8,9 mice subjected to local 4-HT treatment compared with similarly treated ATF2 WT mice (Figures 2G and 2J, left) . To determine whether these lesions represent metastatic melanoma, we collected lymph nodes from Atf2 D8,9/D8,9 and control Atf2 WT/WT mice bearing tumors, which were (either the whole lymph nodes or following partial digestion; Figure S1C ) transplanted into nude mice. Under both approaches, the recipient mice developed tumors, confirming that the clusters of subcapsular S100-positive cells in the lymph nodes of Atf2 D8,9/D8,9
;Braf V600E/V600E ;Pten À/À mice are metastatic melanoma cells. S100 staining of tumors emerging after transplantation confirmed the presence of non-pigmented melanoma cells, as seen in the non-pigmented lymph node source ( Figures 2H and S1D ). In addition, the number of lesions in the lungs was higher in Braf V600E/V600E ;Pten À/À mice harboring Atf2 D8,9/D8,9 versus Atf2 WT/WT (Figures 2I and 2J, right) .
These observations point to the higher metastatic propensity of ATF2 D8,9 expressing melanocytes. mice identified 579 genes (655 probes) that were significantly differentially expressed (Table S1 ). Of these, 305 genes (337 probes) were upregulated and 274 gene (318 probes) were downregulated in Atf2 D8,9/D8,9 tumors compared with Atf2 WT/WT tumors. Genes with significant FDR-adjusted p values were subjected to Ingenuity Pathway Analysis (IPA), which revealed immune receptor and response signaling, angiogenesis, and ROS/NOS signaling components to be among those most significantly altered in the ATF2 D8,9 tumors ( Figure 3C ; Table   S2A ). The respective functional networks predicted to be activated in Atf2 D8,9/D8,9
-expressing tumors included pigmentation, inflammation, cell motility, and invasion (Table S2B) . Representative genes, including S100A8, implicated in macrophage recruitment; Mmp3, Mmp9, and Ccr7, implicated in tumor cell invasion and metastasis; Cxcl9 and Ctla4; and Mitf and related pigmentation genes were confirmed for their increased expression in Atf2 D8,9/D8,9 tumors ( Figure S2D ). Atf2
-driven melanoma indeed exhibits greater pigmentation ( Figure 2F) ;Pten
) mice. The data are the mean ± SEM of n = 4 mice (p < 0.0001 and p = 0.002 by two-tailed unpaired t test). See also Figure S1 . and thus partially resembles mouse Atf2 D8,9 ( Figure 3D ). ATF2 WT and ATF2 SV3 are expressed at varying levels in colon, breast, and prostate tumor cells, whereas ATF2 SV5 exhibited a more selective expression (breast cancer and melanoma cells; Figure S3C ).
Human ATF2 SV5 Phenocopies Mouse Atf2 D8,9 Function
To determine whether ATF2 SV5 elicits oncogenic activities similar to mouse ATF2 D8,9
, we examined human UACC1113 cells, which express high levels of ATF2 SV5 in addition to ATF2 WT and ATF2 SV3 ( Figure S3B ). Silencing of ATF2 SV5 in UACC1113 cells reduced their migration compared to cells in which both ATF2
SV3
and ATF2
WT were silenced ( Figures 3E and S4A ). Furthermore, although colony formation by the UACC91 melanoma cell line (which does not express ATF2 SV5 ; Figure S3B ) was reduced by silencing of endogenous ATF2 ( Figures S4B and S4C animals recapitulates the time course of human melanoma (Balch et al., 2009 (Figures 4I and S4O ).
RNA-seq analysis of H3A cultures identified 434 genes that were upregulated and 580 genes that were downregulated after treatment with siATF2 SV5 compared with control small interfering (si)RNA, but that were not significantly altered following siATF2 WT treatment (Table S3) . IPA analysis identified a number of pathways deregulated by ATF2 SV5 KD ( Figure 4J ). To validate genes that may be commonly deregulated by ATF2 SV5 and ATF2 D8,9 expression, siRNA-mediated KD of ATF2 SV5 and ATF2 WT/SV3 in the human melanoma cell lines LU1205 and C054 ( Figure S4P ) allowed us to assess the changes in the expression of genes identified in our expression studies (Table  S3 ) and IPA analysis ( Figure 4J ). Among the genes confirmed to be altered by both ATF2 variants were CCL4, CCR7, S100A8 (implicated in metastasis), TIM3 (immune checkpoint), and MITF ( Figure 4J ). IPA analyses to identify potential common mechanisms of oncogenic activities for both mouse Atf2 D8,9 and human ATF2
SV5
, identified signaling and networks associated with immune cell infiltration and cell motility in both melanocytes that were subjected to ATF2 SV5 KD in H3A cells and in tumors from Atf2 D8,9/D8,9
; Braf V600E/V600E ;Pten À/À mice (Tables S2B, S4A , and S4B). K   1217  243  795  1263  146  142  1078  794  644  632  1275  624  401  633  772  1658  377  628  629  172  1605  1273  396  268  135  1615  1607  616  1667  519  1070  679 (>3-fold) was found to coincide with poorer prognosis ( Figure 4K ). Of the top 11 highest ATF2 SV5 expressing tumors (quantification cycle (cq) < 33.5), seven (63.6%) were from tumor biopsies obtained shortly after death and four (36.4%) were from patients who were double BRAF/NRAS wild-type. These observations substantiate the findings made in the genetic mouse model as in the cultured melanoma and melanocytes, where transcriptionally inactive ATF2 variants elicit a gain of function oncogenic activity.
DISCUSSION
We identified an unexpected role for transcriptionally inactive ATF2 in melanocyte homeostasis and melanoma development. Atf2 D8,9 alone is able to drive the formation of nevi within 2-3 months and induction of the melanomagenesis. When combined with the Braf mutant genotype, Atf2 D8,9 was able to drive the development of melanoma over 250 days. These animals also exhibit upregulation of select gene networks, including pigmentation-related genes, chemokines/cytokines implicated in the recruitment of immune cells to the tumor sites, and genes related to the enhanced propensity for metastasis. Further, Atf2 D8,9 accelerated the formation of melanomas and increased their propensity to metastasize in Braf/Pten mutant animals. These data establish the ability of a transcriptionally inactive form of ATF2 to promote Braf V600E melanoma development and progression.
Although Atf2 D8,9 enhanced the pigmentation program in both Nras and Braf mutant melanocytes, it attenuated melanoma development in Nras mutant mice and enhanced it in Braf mutant mice. These differences may be attributed to an effect of Atf2 D8,9 on specific signaling pathways that cooperate with Braf, but not Nras, and/or to its effect on tumor microenvironment (i.e., immune editing; tumor stroma). While full-length transcriptionally active ATF2 is largely oncogenic in melanoma, its transcriptionally inactive splice variants, represented by human ATF2 SV5 and modeled by mouse ATF2 D8,9 , exhibit a super-oncogenic function. Genes that were commonly deregulated by expression of both human and mouse variants (ATF2 SV5 and ATF2 D8,9 , respectively) were primarily implicated in metastasis (CCL4, CCR7, S100A8, and MITF), immune cell infiltration (CCL4, CCR7, and TIM3), and melanoma progression / drug resistance (MITF).
Expression of ATF2 SV5 in a series of 33 melanoma biopsies coincides with poor prognosis, consistent with our findings in ATF2 D8,9 mouse melanoma models. Notably, although the activity of ATF2 SV5 is expected to supersede that of other ATF2 forms, it is co-expressed with other ATF2 forms (full-length and other splice variants).
Collectively, our studies provide a genetic support for the involvement of a gain-of-function ATF2 isoform in melanoma. Our data demonstrate that the transcriptionally inactive variant is able to drive melanomagenesis and, in cooperation with mutant Braf, induce melanoma development at the slow rate often seen in human melanoma. Our findings highlight the importance of ATF2 function also as a transcriptionally inactive form.
EXPERIMENTAL PROCEDURES
For additional experimental procedures, see Supplemental Experimental Procedures.
Animal Studies and In Vivo Experiments
All animal studies were approved by the Institutional Animal Care and Use Committee of the Sanford Burnham Prebys Medical Discovery Institute. Atf2 D8,9/D8,9 mice, described in earlier studies (Shah et al., 2010) , were crossed with Braf V600E/V600E ;Pten À/À mice (Dankort et al., 2009) . Atf2 D8,9/D8,9
and Atf2 D8,9/D8,9
;Braf WT/V600E are C57BL/6 and Atf2 D8,9/D8,9
;Braf V600E/V600E ; Pten À/À are C57BL/6 3 129.
Activation of the Tyr::CreER T2 Transgene
Topical administration of 4-HT (Sigma-Aldrich) was performed by application of 10 ml of a 50 mg/ml solution in DMSO with a paintbrush onto the dorsal skin of pups on days 1, 3, and 5 after birth. Local administration of 4-HT was performed by application of 1.5 ml of a 7.8 mg/ml solution in ethanol onto the shaved dorsal skin of 3-week-old mice (Scortegagna et al., 2014) .
Cell Lines
The YUMM1.3 cell line was generated from a Braf WT/V600E ;Pten
melanoma in C57BL/6 mice (Scortegagna et al., 2015) . The human UACC91, (B) Tumor weights of Atf2 D8,9/WT (n = 14), Atf2 WT/WT (n = 16), and Atf2 D8,9/D8,9 (n = 18) mice on a Braf WT/V600E background, 250 days following systemic 4-HT administration. The proportion of Atf2 D8,9/WT , Atf2 D8,9/D8,9 , and Atf2 WT/WT mice developing tumors was 28%, 50%, and 0%, respectively. The data are the mean ± SEM (p value was calculated by two-tailed unpaired t test ) or ATF2
SV5
. The genes analyzed were upregulated in Atf2 D8,9/D8,9 ;Braf
V600E/V600E
;Pten À/À mice (see also Figure S2D Figure S4 and Tables S3   and S4 . The data are the mean ± SEM.
UACC2427, and UACC1113 cell lines were kindly provided by Drs. Brown and Lin. H3A immortalized melanocyte cells were provided by Dr. Bennet (Gray-Schopfer et al., 2006) . All cell lines except H3A were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. H3A cell lines were propagated in 254 media (Gibco) and transferred to DMEM medium prior to initiating the experiments.
Statistical Analysis
Data are presented as means ± SEM or SD and the statistical significance (p value) was determined by two-tailed unpaired t test. Kaplan-Meyer survival curves were compiled using Prism statistical analysis software and significance was assessed using the log rank (Mantel-Cox) test. A p value of < 0.05 was considered significant.
ACCESSION NUMBERS
Microarray datasets were deposited in the NCBI GEO database under GEO: GSE79917 and GSE81014. 
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